Search

Pharma MOU Abcam and Shuwen Biotech Enter into Agreement to Establish Global Alliance

| Editor: Ahlam Rais

Both the companies have signed a MOU for developing high-quality antibodies and CDX kit development.

Related Company

Through the agreement, both the companies will jointly leverage their capabilities, in producing high-quality antibodies and CDX kit development.
Through the agreement, both the companies will jointly leverage their capabilities, in producing high-quality antibodies and CDX kit development.
(Source: Deposit Photos)

Cambridge/UK – Abcam, a global leader in the supply of life science research tools, has recently signed a Memorandum of Understanding (MOU) with Shuwen Biotech, a leading player in the development and commercialisation of companion diagnostics (CDX). Through the agreement, Abcam and Shuwen will jointly leverage their respective capabilities, in producing high-quality antibodies and CDX kit development and commercialisation, to better serve the needs of the pharma industry.

The two parties are responding to the increasing range of development needs from pharmaceutical and biopharma developers, patients, healthcare professionals, and regulatory authorities, The nature of any joint work is yet to be determined in detail but is likely to encompass Abcam providing reproducible highly-specific recombinant antibodies to key targets, which Shuwen will incorporate into companion diagnostic kits.

Both the companies will focus on developing efficient and comprehensive solutions to advance clinical diagnostics and precision medicine, faster

(ID:45293900)